T1	p 109 208	patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study ( KOARA study ) .
T2	p 456 534	nifedipine SR group ( Group N ) or the Ginkgo biloba extract group ( Group G )
T3	p 740 786	Ninety-three subjects were randomly assigned .
T4	p 1114 1131	Korean patients .
T5	p 1171 1184	RP patients .
T6	i 44 72	nifedipine sustained release
T7	i 78 99	Ginkgo biloba extract
T8	i 256 302	nifedipine sustained release ( nifedipine SR )
T9	i 317 338	Ginkgo biloba extract
T10	i 456 487	nifedipine SR group ( Group N )
T11	i 495 522	Ginkgo biloba extract group
T12	i 531 534	G )
T13	i 1023 1036	nifedipine SR
T14	i 1061 1082	Ginkgo biloba extract
T15	o 21 29	efficacy
T16	o 34 40	safety
T17	o 233 241	efficacy
T18	o 246 252	safety
T19	o 650 691	percent improvement of the RP attack rate
T20	o 911 933	serious adverse events
T21	o 949 980	almost adverse events were mild
T22	o 1046 1055	effective
T23	o 1148 1157	tolerable